MorphoSys AG said its AbD Serotec business unit has received a multiple research antibody order from Proteomika SL, a Spanish biotechnology company specialising in biomarker discovery. Proteomika has ordered novel, HuCAL-based, research antibodies against a broad range of target molecules in addition to the production of antigen material at AbD Serotec.

AbD Serotec will apply MorphoSys's HuCAL GOLD antibody technology and the proprietary Antigen Expression System AgX. The order ranks Proteomika among the largest customers for custom monoclonals services provided by AbD Serotec. Financial details of the agreement were not disclosed.

While announcing this agreement Dr. Laureano Simon, chief executive officer, Proteomika, said "Proteomika is delighted to announce this agreement with AbD Serotec - the industry leader in providing tailored antibodies for research applications. The fast turn around in antibody production offered by AbD Serotec, together with the high quality of the resulting antibodies, will help accelerate the process of biomarker identification and validation, allowing Proteomika to bring new diagnostic and prognostic tools for human diseases to the market in the shortest possible timeframe."

Proteomika was established in 2002 as a subsidiary of the leading genomics company Progenika Biopharma SA with the objective of exploiting advances in biomarker research for the development of diagnostic and prognostic products.

"We welcome the decision of Proteomika to use HuCAL GOLD research antibodies in its proteomics programs," said Dr. Simon Moroney, chief executive officer, MorphoSys AG. "This order is one of the largest generated by AbD Serotec, and highlights the advantage of our HuCAL technology in bespoke proteomics applications."

MorphoSys is a biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases.